Dr Reddy's reports unexpected quarterly loss; Teva to donate $7M worth of meds to Haitian relief;

> India's Dr Reddy's Laboratories reported an unexpected loss for the latest quarter after incurring write-off related losses at its German unit and trimmed revenue growth forecast for this fiscal year. Report

> Teva Pharmaceutical Industries announced today that it will be donating over $7 million in medicine to benefit earthquake victims in Haiti. Report

> Forest Laboratories said its profit grew 12 percent in the fiscal third quarter due to stronger sales of its Alzheimer's disease treatment Namenda as well as newer drugs. Report

> Novartis says Japanese authorities have approved three of its drugs for the treatment of diseases affecting millions in that country, the group's second-largest pharmaceutical market. Release

> Novo Nordisk says Japanese health officials have approved its Victoza drug for treatment of Type 2 diabetes, and it would launch the product in the first half of 2010. Release

> Drugmaker Lupin has received an FDA approval for its Mandideep facility, which had been the subject of a warning letter. Report

> Switzerland's medical regulator recommended patients with serious autoimmune diseases should not use Novartis' H1N1 vaccine, saying there were no studies assessing the inoculation in that population segment. Report

> Johnson & Johnson's Cordis unit has again sued Boston Scientific, claiming its Promus drug-coated stent wrongfully uses three of Cordis's patents without permission. Report

> Endo Pharmaceuticals said it was reviewing and intending to defend against an attempt by a competitor to produce a generic version of Lidoderm, a skin patch for neuralgia pain. Report

Biotech News

> GlaxoSmithKline is opening up its in-house R&D work involving more than 2 million molecules in hopes of spurring some fresh thinking on malaria vaccines. Story

> Xconomy stuck its toe in the San Diego biotech waters and found that the job market appears to be heating up after a long chilly spell. Report

> Shares of Lexicon Pharmaceuticals (LXRX) jumped 24 percent this morning after the developer reported promising signs that its Type 2 diabetes drug lowered blood glucose levels in a mid-stage trial. Story

> A group of fiscal watchdogs for the Florida Legislature has been doing the math on the Sunshine State's $759 million investment in eight biotech campuses over the last six years. The payback: 1,100 jobs, without any significant clustering of biotech startups. Report

> It's been more than two years since a Boston biotech went public, but now two are at the starting gate and a prominent local lawyer says he knows of six more that are actively laying the foundation for an IPO. Story

> The pundits are working overtime this morning trying to assess the structural damage that Massachusetts voters inflicted on the healthcare reform bill yesterday. Report

Manufacturing News

> Op-Ed: Tylenol has lost its way. Article

> Drug company manufacturing operations are far from lean. In a long-term cross-industry study that uses inventory turns as an indicator, pharmaceutical companies hold the bottom spot. Article

> Six biopharma companies have so far signed with Sharps Compliance Corp. to manage the return of syringes from consumers. Report

> Drug giant GlaxoSmithKline is fighting counterfeiters who have targeted its over-the-counter weight-loss product, Alli. GSK report

> The yeoman wooden pallet, a trustworthy supply-chain agent for some 60 years, is under attack. Much of the public, thanks to most of the media coverage, has placed blame for the 50-million-unit J&J McNeil product recall on contamination caused by a chemical byproduct of a treatment used on pallet wood. Article

And Finally... Are Omega-3 fatty acids an anti-aging tonic? Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.